カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のドーパミン作動薬市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Dopamine Agonists Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19271）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19271
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：102
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のドーパミン作動薬市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

ドーパミン作動薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のドーパミン作動薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ドーパミン作動薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・エルゴタミン、非エルゴタミン

用途別セグメントは次のように区分されます。
・パーキンソン病、むずむず脚症候群

世界のドーパミン作動薬市場の主要な市場プレーヤーは以下のとおりです。
・Pfizer、GSK、Roche、Merck、UCB、Teva Pharmaceutical Industries Ltd、ACADIA Pharmaceuticals Inc、Impax Laboratories、AbbVie、Boehringer Ingelheim、Otsuka Pharmaceutical Co、Kissei Pharmaceutical Co

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、ドーパミン作動薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なドーパミン作動薬メーカーの企業概要、2019年～2022年までのドーパミン作動薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なドーパミン作動薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ドーパミン作動薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのドーパミン作動薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのドーパミン作動薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびドーパミン作動薬の産業チェーンを掲載しています。
・第13、14、15章では、ドーパミン作動薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- ドーパミン作動薬の概要
- 種類別分析（2017年vs2021年vs2028年）：エルゴタミン、非エルゴタミン
- 用途別分析（2017年vs2021年vs2028年）：パーキンソン病、むずむず脚症候群
- 世界のドーパミン作動薬市場規模・予測
- 世界のドーパミン作動薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Pfizer、GSK、Roche、Merck、UCB、Teva Pharmaceutical Industries Ltd、ACADIA Pharmaceuticals Inc、Impax Laboratories、AbbVie、Boehringer Ingelheim、Otsuka Pharmaceutical Co、Kissei Pharmaceutical Co
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：エルゴタミン、非エルゴタミン
・用途別分析2017年-2028年：パーキンソン病、むずむず脚症候群
・ドーパミン作動薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・ドーパミン作動薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・ドーパミン作動薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・ドーパミン作動薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・ドーパミン作動薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Dopamine Agonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Dopamine Agonists market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Parkinson’s accounting for % of the Dopamine Agonists global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Ergotamine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Dopamine Agonists include Pfizer, GSK, Roche, Merck, and UCB, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Dopamine Agonists market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Ergotamine
Non-ergotamine
Market segment by Application can be divided into
Parkinson’s
Restless Legs Syndrome
The key market players for global Dopamine Agonists market are listed below:
Pfizer
GSK
Roche
Merck
UCB
Teva Pharmaceutical Industries Ltd
ACADIA Pharmaceuticals Inc
Impax Laboratories
AbbVie
Boehringer Ingelheim
Otsuka Pharmaceutical Co
Kissei Pharmaceutical Co
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Dopamine Agonists product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Dopamine Agonists, with price, sales, revenue and global market share of Dopamine Agonists from 2019 to 2022.
Chapter 3, the Dopamine Agonists competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Dopamine Agonists breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Dopamine Agonists market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Dopamine Agonists.
Chapter 13, 14, and 15, to describe Dopamine Agonists sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Dopamine Agonists Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Dopamine Agonists Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Ergotamine
1.2.3 Non-ergotamine
1.3 Market Analysis by Application
1.3.1 Overview: Global Dopamine Agonists Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Parkinson’s
1.3.3 Restless Legs Syndrome
1.4 Global Dopamine Agonists Market Size & Forecast
1.4.1 Global Dopamine Agonists Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Dopamine Agonists Sales in Volume (2017-2028)
1.4.3 Global Dopamine Agonists Price (2017-2028)
1.5 Global Dopamine Agonists Production Capacity Analysis
1.5.1 Global Dopamine Agonists Total Production Capacity (2017-2028)
1.5.2 Global Dopamine Agonists Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Dopamine Agonists Market Drivers
1.6.2 Dopamine Agonists Market Restraints
1.6.3 Dopamine Agonists Trends Analysis
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Dopamine Agonists Product and Services
2.1.4 Pfizer Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Dopamine Agonists Product and Services
2.2.4 GSK Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Dopamine Agonists Product and Services
2.3.4 Roche Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Dopamine Agonists Product and Services
2.4.4 Merck Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 UCB
2.5.1 UCB Details
2.5.2 UCB Major Business
2.5.3 UCB Dopamine Agonists Product and Services
2.5.4 UCB Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Teva Pharmaceutical Industries Ltd
2.6.1 Teva Pharmaceutical Industries Ltd Details
2.6.2 Teva Pharmaceutical Industries Ltd Major Business
2.6.3 Teva Pharmaceutical Industries Ltd Dopamine Agonists Product and Services
2.6.4 Teva Pharmaceutical Industries Ltd Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 ACADIA Pharmaceuticals Inc
2.7.1 ACADIA Pharmaceuticals Inc Details
2.7.2 ACADIA Pharmaceuticals Inc Major Business
2.7.3 ACADIA Pharmaceuticals Inc Dopamine Agonists Product and Services
2.7.4 ACADIA Pharmaceuticals Inc Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Impax Laboratories
2.8.1 Impax Laboratories Details
2.8.2 Impax Laboratories Major Business
2.8.3 Impax Laboratories Dopamine Agonists Product and Services
2.8.4 Impax Laboratories Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 AbbVie
2.9.1 AbbVie Details
2.9.2 AbbVie Major Business
2.9.3 AbbVie Dopamine Agonists Product and Services
2.9.4 AbbVie Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Boehringer Ingelheim
2.10.1 Boehringer Ingelheim Details
2.10.2 Boehringer Ingelheim Major Business
2.10.3 Boehringer Ingelheim Dopamine Agonists Product and Services
2.10.4 Boehringer Ingelheim Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Otsuka Pharmaceutical Co
2.11.1 Otsuka Pharmaceutical Co Details
2.11.2 Otsuka Pharmaceutical Co Major Business
2.11.3 Otsuka Pharmaceutical Co Dopamine Agonists Product and Services
2.11.4 Otsuka Pharmaceutical Co Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Kissei Pharmaceutical Co
2.12.1 Kissei Pharmaceutical Co Details
2.12.2 Kissei Pharmaceutical Co Major Business
2.12.3 Kissei Pharmaceutical Co Dopamine Agonists Product and Services
2.12.4 Kissei Pharmaceutical Co Dopamine Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Dopamine Agonists Breakdown Data by Manufacturer
3.1 Global Dopamine Agonists Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Dopamine Agonists Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Dopamine Agonists
3.4 Market Concentration Rate
3.4.1 Top 3 Dopamine Agonists Manufacturer Market Share in 2021
3.4.2 Top 6 Dopamine Agonists Manufacturer Market Share in 2021
3.5 Global Dopamine Agonists Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Dopamine Agonists Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Dopamine Agonists Market Size by Region
4.1.1 Global Dopamine Agonists Sales in Volume by Region (2017-2028)
4.1.2 Global Dopamine Agonists Revenue by Region (2017-2028)
4.2 North America Dopamine Agonists Revenue (2017-2028)
4.3 Europe Dopamine Agonists Revenue (2017-2028)
4.4 Asia-Pacific Dopamine Agonists Revenue (2017-2028)
4.5 South America Dopamine Agonists Revenue (2017-2028)
4.6 Middle East and Africa Dopamine Agonists Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Dopamine Agonists Sales in Volume by Type (2017-2028)
5.2 Global Dopamine Agonists Revenue by Type (2017-2028)
5.3 Global Dopamine Agonists Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Dopamine Agonists Sales in Volume by Application (2017-2028)
6.2 Global Dopamine Agonists Revenue by Application (2017-2028)
6.3 Global Dopamine Agonists Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Dopamine Agonists Sales by Type (2017-2028)
7.2 North America Dopamine Agonists Sales by Application (2017-2028)
7.3 North America Dopamine Agonists Market Size by Country
7.3.1 North America Dopamine Agonists Sales in Volume by Country (2017-2028)
7.3.2 North America Dopamine Agonists Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Dopamine Agonists Sales by Type (2017-2028)
8.2 Europe Dopamine Agonists Sales by Application (2017-2028)
8.3 Europe Dopamine Agonists Market Size by Country
8.3.1 Europe Dopamine Agonists Sales in Volume by Country (2017-2028)
8.3.2 Europe Dopamine Agonists Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Dopamine Agonists Sales by Type (2017-2028)
9.2 Asia-Pacific Dopamine Agonists Sales by Application (2017-2028)
9.3 Asia-Pacific Dopamine Agonists Market Size by Region
9.3.1 Asia-Pacific Dopamine Agonists Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Dopamine Agonists Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Dopamine Agonists Sales by Type (2017-2028)
10.2 South America Dopamine Agonists Sales by Application (2017-2028)
10.3 South America Dopamine Agonists Market Size by Country
10.3.1 South America Dopamine Agonists Sales in Volume by Country (2017-2028)
10.3.2 South America Dopamine Agonists Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Dopamine Agonists Sales by Type (2017-2028)
11.2 Middle East & Africa Dopamine Agonists Sales by Application (2017-2028)
11.3 Middle East & Africa Dopamine Agonists Market Size by Country
11.3.1 Middle East & Africa Dopamine Agonists Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Dopamine Agonists Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Dopamine Agonists and Key Manufacturers
12.2 Manufacturing Costs Percentage of Dopamine Agonists
12.3 Dopamine Agonists Production Process
12.4 Dopamine Agonists Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Dopamine Agonists Typical Distributors
13.3 Dopamine Agonists Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Dopamine Agonists Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Dopamine Agonists Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Dopamine Agonists Product and Services
Table 6. Pfizer Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. GSK Basic Information, Manufacturing Base and Competitors
Table 8. GSK Major Business
Table 9. GSK Dopamine Agonists Product and Services
Table 10. GSK Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Roche Basic Information, Manufacturing Base and Competitors
Table 12. Roche Major Business
Table 13. Roche Dopamine Agonists Product and Services
Table 14. Roche Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Merck Basic Information, Manufacturing Base and Competitors
Table 16. Merck Major Business
Table 17. Merck Dopamine Agonists Product and Services
Table 18. Merck Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. UCB Basic Information, Manufacturing Base and Competitors
Table 20. UCB Major Business
Table 21. UCB Dopamine Agonists Product and Services
Table 22. UCB Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Teva Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 24. Teva Pharmaceutical Industries Ltd Major Business
Table 25. Teva Pharmaceutical Industries Ltd Dopamine Agonists Product and Services
Table 26. Teva Pharmaceutical Industries Ltd Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. ACADIA Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 28. ACADIA Pharmaceuticals Inc Major Business
Table 29. ACADIA Pharmaceuticals Inc Dopamine Agonists Product and Services
Table 30. ACADIA Pharmaceuticals Inc Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Impax Laboratories Basic Information, Manufacturing Base and Competitors
Table 32. Impax Laboratories Major Business
Table 33. Impax Laboratories Dopamine Agonists Product and Services
Table 34. Impax Laboratories Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. AbbVie Basic Information, Manufacturing Base and Competitors
Table 36. AbbVie Major Business
Table 37. AbbVie Dopamine Agonists Product and Services
Table 38. AbbVie Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 40. Boehringer Ingelheim Major Business
Table 41. Boehringer Ingelheim Dopamine Agonists Product and Services
Table 42. Boehringer Ingelheim Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Otsuka Pharmaceutical Co Basic Information, Manufacturing Base and Competitors
Table 44. Otsuka Pharmaceutical Co Major Business
Table 45. Otsuka Pharmaceutical Co Dopamine Agonists Product and Services
Table 46. Otsuka Pharmaceutical Co Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Kissei Pharmaceutical Co Basic Information, Manufacturing Base and Competitors
Table 48. Kissei Pharmaceutical Co Major Business
Table 49. Kissei Pharmaceutical Co Dopamine Agonists Product and Services
Table 50. Kissei Pharmaceutical Co Dopamine Agonists Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Global Dopamine Agonists Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 52. Global Dopamine Agonists Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 53. Market Position of Manufacturers in Dopamine Agonists, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 54. Global Dopamine Agonists Production Capacity by Company, (K Units): 2020 VS 2021
Table 55. Head Office and Dopamine Agonists Production Site of Key Manufacturer
Table 56. Dopamine Agonists New Entrant and Capacity Expansion Plans
Table 57. Dopamine Agonists Mergers & Acquisitions in the Past Five Years
Table 58. Global Dopamine Agonists Sales by Region (2017-2022) & (K Units)
Table 59. Global Dopamine Agonists Sales by Region (2023-2028) & (K Units)
Table 60. Global Dopamine Agonists Revenue by Region (2017-2022) & (USD Million)
Table 61. Global Dopamine Agonists Revenue by Region (2023-2028) & (USD Million)
Table 62. Global Dopamine Agonists Sales by Type (2017-2022) & (K Units)
Table 63. Global Dopamine Agonists Sales by Type (2023-2028) & (K Units)
Table 64. Global Dopamine Agonists Revenue by Type (2017-2022) & (USD Million)
Table 65. Global Dopamine Agonists Revenue by Type (2023-2028) & (USD Million)
Table 66. Global Dopamine Agonists Price by Type (2017-2022) & (USD/Unit)
Table 67. Global Dopamine Agonists Price by Type (2023-2028) & (USD/Unit)
Table 68. Global Dopamine Agonists Sales by Application (2017-2022) & (K Units)
Table 69. Global Dopamine Agonists Sales by Application (2023-2028) & (K Units)
Table 70. Global Dopamine Agonists Revenue by Application (2017-2022) & (USD Million)
Table 71. Global Dopamine Agonists Revenue by Application (2023-2028) & (USD Million)
Table 72. Global Dopamine Agonists Price by Application (2017-2022) & (USD/Unit)
Table 73. Global Dopamine Agonists Price by Application (2023-2028) & (USD/Unit)
Table 74. North America Dopamine Agonists Sales by Country (2017-2022) & (K Units)
Table 75. North America Dopamine Agonists Sales by Country (2023-2028) & (K Units)
Table 76. North America Dopamine Agonists Revenue by Country (2017-2022) & (USD Million)
Table 77. North America Dopamine Agonists Revenue by Country (2023-2028) & (USD Million)
Table 78. North America Dopamine Agonists Sales by Type (2017-2022) & (K Units)
Table 79. North America Dopamine Agonists Sales by Type (2023-2028) & (K Units)
Table 80. North America Dopamine Agonists Sales by Application (2017-2022) & (K Units)
Table 81. North America Dopamine Agonists Sales by Application (2023-2028) & (K Units)
Table 82. Europe Dopamine Agonists Sales by Country (2017-2022) & (K Units)
Table 83. Europe Dopamine Agonists Sales by Country (2023-2028) & (K Units)
Table 84. Europe Dopamine Agonists Revenue by Country (2017-2022) & (USD Million)
Table 85. Europe Dopamine Agonists Revenue by Country (2023-2028) & (USD Million)
Table 86. Europe Dopamine Agonists Sales by Type (2017-2022) & (K Units)
Table 87. Europe Dopamine Agonists Sales by Type (2023-2028) & (K Units)
Table 88. Europe Dopamine Agonists Sales by Application (2017-2022) & (K Units)
Table 89. Europe Dopamine Agonists Sales by Application (2023-2028) & (K Units)
Table 90. Asia-Pacific Dopamine Agonists Sales by Region (2017-2022) & (K Units)
Table 91. Asia-Pacific Dopamine Agonists Sales by Region (2023-2028) & (K Units)
Table 92. Asia-Pacific Dopamine Agonists Revenue by Region (2017-2022) & (USD Million)
Table 93. Asia-Pacific Dopamine Agonists Revenue by Region (2023-2028) & (USD Million)
Table 94. Asia-Pacific Dopamine Agonists Sales by Type (2017-2022) & (K Units)
Table 95. Asia-Pacific Dopamine Agonists Sales by Type (2023-2028) & (K Units)
Table 96. Asia-Pacific Dopamine Agonists Sales by Application (2017-2022) & (K Units)
Table 97. Asia-Pacific Dopamine Agonists Sales by Application (2023-2028) & (K Units)
Table 98. South America Dopamine Agonists Sales by Country (2017-2022) & (K Units)
Table 99. South America Dopamine Agonists Sales by Country (2023-2028) & (K Units)
Table 100. South America Dopamine Agonists Revenue by Country (2017-2022) & (USD Million)
Table 101. South America Dopamine Agonists Revenue by Country (2023-2028) & (USD Million)
Table 102. South America Dopamine Agonists Sales by Type (2017-2022) & (K Units)
Table 103. South America Dopamine Agonists Sales by Type (2023-2028) & (K Units)
Table 104. South America Dopamine Agonists Sales by Application (2017-2022) & (K Units)
Table 105. South America Dopamine Agonists Sales by Application (2023-2028) & (K Units)
Table 106. Middle East & Africa Dopamine Agonists Sales by Region (2017-2022) & (K Units)
Table 107. Middle East & Africa Dopamine Agonists Sales by Region (2023-2028) & (K Units)
Table 108. Middle East & Africa Dopamine Agonists Revenue by Region (2017-2022) & (USD Million)
Table 109. Middle East & Africa Dopamine Agonists Revenue by Region (2023-2028) & (USD Million)
Table 110. Middle East & Africa Dopamine Agonists Sales by Type (2017-2022) & (K Units)
Table 111. Middle East & Africa Dopamine Agonists Sales by Type (2023-2028) & (K Units)
Table 112. Middle East & Africa Dopamine Agonists Sales by Application (2017-2022) & (K Units)
Table 113. Middle East & Africa Dopamine Agonists Sales by Application (2023-2028) & (K Units)
Table 114. Dopamine Agonists Raw Material
Table 115. Key Manufacturers of Dopamine Agonists Raw Materials
Table 116. Direct Channel Pros & Cons
Table 117. Indirect Channel Pros & Cons
Table 118. Dopamine Agonists Typical Distributors
Table 119. Dopamine Agonists Typical Customers
List of Figures
Figure 1. Dopamine Agonists Picture
Figure 2. Global Dopamine Agonists Revenue Market Share by Type in 2021
Figure 3. Ergotamine
Figure 4. Non-ergotamine
Figure 5. Global Dopamine Agonists Revenue Market Share by Application in 2021
Figure 6. Parkinson's
Figure 7. Restless Legs Syndrome
Figure 8. Global Dopamine Agonists Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Dopamine Agonists Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Dopamine Agonists Sales (2017-2028) & (K Units)
Figure 11. Global Dopamine Agonists Price (2017-2028) & (USD/Unit)
Figure 12. Global Dopamine Agonists Production Capacity (2017-2028) & (K Units)
Figure 13. Global Dopamine Agonists Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Dopamine Agonists Market Drivers
Figure 15. Dopamine Agonists Market Restraints
Figure 16. Dopamine Agonists Market Trends
Figure 17. Global Dopamine Agonists Sales Market Share by Manufacturer in 2021
Figure 18. Global Dopamine Agonists Revenue Market Share by Manufacturer in 2021
Figure 19. Dopamine Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Dopamine Agonists Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Dopamine Agonists Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Dopamine Agonists Sales Market Share by Region (2017-2028)
Figure 23. Global Dopamine Agonists Revenue Market Share by Region (2017-2028)
Figure 24. North America Dopamine Agonists Revenue (2017-2028) & (USD Million)
Figure 25. Europe Dopamine Agonists Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Dopamine Agonists Revenue (2017-2028) & (USD Million)
Figure 27. South America Dopamine Agonists Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Dopamine Agonists Revenue (2017-2028) & (USD Million)
Figure 29. Global Dopamine Agonists Sales Market Share by Type (2017-2028)
Figure 30. Global Dopamine Agonists Revenue Market Share by Type (2017-2028)
Figure 31. Global Dopamine Agonists Price by Type (2017-2028) & (USD/Unit)
Figure 32. Global Dopamine Agonists Sales Market Share by Application (2017-2028)
Figure 33. Global Dopamine Agonists Revenue Market Share by Application (2017-2028)
Figure 34. Global Dopamine Agonists Price by Application (2017-2028) & (USD/Unit)
Figure 35. North America Dopamine Agonists Sales Market Share by Type (2017-2028)
Figure 36. North America Dopamine Agonists Sales Market Share by Application (2017-2028)
Figure 37. North America Dopamine Agonists Sales Market Share by Country (2017-2028)
Figure 38. North America Dopamine Agonists Revenue Market Share by Country (2017-2028)
Figure 39. United States Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Dopamine Agonists Sales Market Share by Type (2017-2028)
Figure 43. Europe Dopamine Agonists Sales Market Share by Application (2017-2028)
Figure 44. Europe Dopamine Agonists Sales Market Share by Country (2017-2028)
Figure 45. Europe Dopamine Agonists Revenue Market Share by Country (2017-2028)
Figure 46. Germany Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Dopamine Agonists Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Dopamine Agonists Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Dopamine Agonists Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Dopamine Agonists Revenue Market Share by Region (2017-2028)
Figure 55. China Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Dopamine Agonists Sales Market Share by Type (2017-2028)
Figure 62. South America Dopamine Agonists Sales Market Share by Application (2017-2028)
Figure 63. South America Dopamine Agonists Sales Market Share by Country (2017-2028)
Figure 64. South America Dopamine Agonists Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Dopamine Agonists Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Dopamine Agonists Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Dopamine Agonists Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Dopamine Agonists Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Dopamine Agonists Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Dopamine Agonists in 2021
Figure 76. Manufacturing Process Analysis of Dopamine Agonists
Figure 77. Dopamine Agonists Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • THR-βアゴニストのグローバル市場展望 2023年-2029年：仕様10mg以下、仕様10-50mg、仕様50mg以上
  • 世界のニコチン作動薬市場2022年：市場規模予測（～2028年）
  • 世界の抗糖尿病グルカゴン様ペプチド1アゴニスト市場2022年：市場規模予測（～2028年）
  • 世界のパーキンソン病治療薬市場2022年：市場規模予測（～2028年）
  • 世界の医薬品用キシリトール市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19271 )"世界のドーパミン作動薬市場2022年：市場規模予測（～2028年）" (英文：Global Dopamine Agonists Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。